Suven Life Sciences Ltd

Suven Life Sciences Ltd share price advanced by 5.64% to Rs 327.8 after the company's net profit jumped 179.85% to Rs 127.61 crore, while revenue from operations increased sharply by 134.87% to Rs 3.57 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Research, Analytics & Technology industry group stocks on BSE stood at Rs 41117.62 crore, retreating 10.12%. It has improved by 4.92% over last one week and crept higher by 5.03% in last one month while the market capitalization of Suven Life Sciences Ltd has marginally improved by 9.41% and 56.69% in the same period respectively. Profit before tax (PBT) of Suven Life Sciences Ltd stood at Rs 127.61 crore in Q2 FY26, surging by 147.69% year-on-year, and expanding by 179.85% quarter-on-quarter. EBITDA came in at Rs 140 crore, rallying 172.68% YoY and jumping 143.85% sequentially. Total expenses jumped by 157.20% to Rs 138.22 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 7.28 crore, witnessing a strong rise of 24.87% YoY. For the TTM ended FY26, revenue from operations tick up 6.76% to Rs 7.11 crore, while net profit soared by 71.91% to Rs 276.34 crore, compared to previous TTM. EBITDA plunged by 17789% to Rs 298.44 crore, and PBT witnessed a strong rise of 71.91% to Rs 276.34 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 301.79 crore in FY26, as against Rs 154.1 crore in FY25. Suven Life Sciences Ltd rallied 22.11% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.

Suven Life Sciences Limited will hold a board meeting on Thursday, August 6, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, and related matters, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for the company was closed from July 1, 2026, and will remain closed for 48 hours after the financial results are declared.

The company’s Business Responsibility and Sustainability Report indicates adherence to environmental laws and regulations, with waste managed through authorized agencies and a policy in place for addressing community grievances. A significant portion of input materials, 21%, are directly sourced from micro, small, and medium enterprises within India, while 46% of total wage costs are allocated to employees in semi-urban areas. The report notes no projects requiring environmental impact assessments or rehabilitation and resettlement initiatives, although the company’s research and development focus limits opportunities for product turnover. Furthermore, the company reports no data breaches and maintains a cyber security policy accessible online, though further detail on the sustainability practices of its suppliers could be valuable.

Suven Life Sciences announced that the 37th Annual General Meeting(AGM) of the company will be held on 25 August 2026.

Net Loss of Suven Life Sciences reported to Rs 45.60 crore in the quarter ended March 2026 as against net loss of Rs 43.94 crore during the previous quarter ended March 2025. Sales rose 3.40% to Rs 1.52 crore in the quarter ended March 2026 as against Rs 1.47 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 276.34 crore in the year ended March 2026 as against net loss of Rs 160.75 crore during the previous year ended March 2025. Sales rose 6.76% to Rs 7.11 crore in the year ended March 2026 as against Rs 6.66 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1.521.47 3 7.116.66 7 OPM %-3331.58-2980.95 --4001.41-2489.19 - PBDT-44.01-42.60 -3 -270.73-154.92 -75 PBT-45.60-43.94 -4 -276.34-160.75 -72 NP-45.60-43.94 -4 -276.34-160.75 -72 Powered by Capital Market - Live

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May 2026.

Suven Life Sciences has allotted 3,17,68,764 equity shares of Re 1 each on conversion of warrants. Post allotment, the paid up equity share capital has increased to 2637,20,583 equity shares of Re 1 each. Powered by Capital Market - Live

Suven Life Sciences has allotted 44,77,612 equity shares on preferential basis up on conversion of equivalent number of convertible warrants. Consequently, the paid up equity share capital has increased to 23,19,51,819 equity shares of Re 1 each. Powered by Capital Market - Live

Net Loss of Suven Life Sciences reported to Rs 101.92 crore in the quarter ended December 2025 as against net loss of Rs 39.12 crore during the previous quarter ended December 2024. Sales rose 74.53% to Rs 2.81 crore in the quarter ended December 2025 as against Rs 1.61 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2.811.61 75 OPM %-3677.94-2435.40 - PBDT-100.58-37.58 -168 PBT-101.92-39.12 -161 NP-101.92-39.12 -161 Powered by Capital Market - Live

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live